Pharmaceuticals

Personalized Medicine Adoption Boosting Growth in the Biologics Market

March 18, 2026March 18, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Biologics Market During 2026–2030?

The biologics market size has shown substantial growth over recent years. It is projected to expand from $495.56 billion in 2025 to $540.46 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.1%. The expansion observed historically can be attributed to factors such as constrained availability of biologics, a dependence on traditional therapies, the increasing occurrence of immune-related disorders, improvements in healthcare infrastructure, and heightened physician awareness and prescribing practices.

The biologics market is projected to experience substantial expansion over the coming years. Its valuation is anticipated to reach $827.24 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.2%. Factors contributing to this growth during the forecast period include the creation of new monoclonal antibodies, the broader use of mRNA and viral vector vaccines, the rising implementation of personalized biologic treatments, increased government backing and investment in biologics, and the integration of digital health with patient monitoring systems. Key trends for the forecast period encompass the increasing acceptance of monoclonal antibodies and therapeutic proteins, advancements in vaccine development, such as mRNA and viral vector vaccines, the wider availability of prescription-based biologics and their distribution through hospital pharmacies, a heightened emphasis on personalized medicine and specialized biologic therapies, and the incorporation of biologics with cutting-edge healthcare solutions and patient observation.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3606&type=smp

Which Major Factors Are Driving The Expansion Of The Biologics Market?

The global biologics market is experiencing substantial growth, primarily driven by the escalating demand for personalized medicine. This medical approach, also known as precision medicine, involves tailoring healthcare and treatment plans to the unique characteristics of each patient. Personalized medicine enables the customization of biological treatments according to a patient’s specific genetic and clinical profile, thereby transforming the healthcare landscape. For instance, in February 2024, the Personalized Medicine Coalition, a US-based hospital and health care organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, an increase from six approvals in 2022. Consequently, the rising demand for personalized medicine is expected to continue fueling the expansion of the biologics market moving forward.

How Are The Various Segments Of The Biologics Market Categorized?

The biologics market covered in this report is segmented –

1) By Type: Monoclonal Antibodies (MAbS), Therapeutic Proteins, Vaccines

2) By Drug Classification: Branded Drugs, Generic Drugs

3) By Route Of Administration: Oral, Other Route Of Administration

4) By Mode Of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies Or Drug Stores, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies (MAbs): Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies

2) By Therapeutic Proteins: Hormones, Enzymes, Cytokines, Fusion Proteins

3) By Vaccines: Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, mRNA Vaccines, Viral Vector Vaccines

What Trends Are Affecting The Expansion Of The Biologics Market?

Leading companies in the biologics market are prioritizing the development of innovative products, such as biosimilars, to offer more economical alternatives to traditional biologic treatments. Biosimilars are biologic products that closely resemble an already approved reference biologic, demonstrating no major differences in terms of safety, effectiveness, or quality, which helps in reducing therapy costs and broadening patient access to advanced medical options. For example, in July 2025, Biocon Biologics, a division of the India-based biopharmaceutical company Biocon Limited, introduced Nepexto, a biosimilar to Enbrel (etanercept), in Australia. Nepexto is a fusion-protein biologic engineered to inhibit tumor necrosis factor-alpha (TNF-a), a principal inflammatory mediator in various autoimmune conditions. It comprises a recombinant DNA-derived protein that mirrors the binding action of the original etanercept molecule, thus delivering comparable efficacy and safety while simultaneously making treatment more widely available. Its distinctive characteristics include a high degree of biosimilarity, validated by robust clinical data and regulatory approvals, along with an established distribution channel through its local partner Generic Health, solidifying its position as a viable option for the long-term management of diseases such as rheumatoid arthritis, psoriasis, and ankylosing spondylitis.

Which Major Firms Influence Developments In The Biologics Market?

Major companies operating in the biologics market are Merck & Co. Inc., AbbVie Inc., F. Hoffmann-La Roche AG, Johnson & Johnson, Pfizer Inc., Bristol Myers Squibb Company, Sanofi S.A., GlaxoSmithKline Plc., Eli Lilly and Company, Amgen Inc., Shanghai Fosun Pharmaceuticals, Bayer AG, Novartis AG, BiosanaPharma, WuXi, Teva UK Limited, AstraZeneca, Abbott Laboratories, Vectura Group, Fujifilm, Lonza, Seqens, Piramal Pharma Solutions, Corden Pharma, Procos SpA and BSP Pharmaceuticals., Microgen, Geropharm, Valenta, NovaMedica, SynBi, Rani Therapeutics, Enteris BioPharma, Allena Pharmaceuticals, Biogen Inc., Emisphere Technologies Inc., Apotex, Gilead Sciences

Read the full biologics market report here:

https://www.thebusinessresearchcompany.com/report/biologics-global-market-report

Which Region Currently Holds The Largest Share Of The Biologics Market?

North America was the largest region in the biologics market in 2025. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Biologics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3606&type=smp

Browse Through More Reports Similar to the Global Biologics Market 2026, By The Business Research Company

Cancer Biologics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Orthobiologics Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/orthobiologics-devices-and-equipment-global-market-report

Oral Biologics And Biosimilar Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilar-drug-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795